Consistent with this finding, activity of immunoproteasome inhibitors was described in two acute lymphoblastic leukemia (ALL) cell lines harboring KMT2A::AFF1 (MLL-AF4) fusions [18]. Here, KMT2A is linked to acute lymphoblastic leukemia.